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A two-serine insertion at position 69 (i69SS) of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) appears to be
critical to enhance multi-nucleoside RT inhibitor resistance (MNR) in the sequence context of multiple zidovudine (AZT) resistance
mutations (i.e., M41L, L210W, T215Y). In this study, we measured the replication capacity relative to the wild-type (WT) HIV-1 of a series
of recombinant viruses carrying the i69SS in the background of a clinical isolate with MNR in which we introduced mutations D67N, Y215T,
Y215S, or Y215N. In vitro measurements included replication kinetics and growth competition assays at different multiplicities of infection
(MOI). While the addition of D67N had a minor effect on replication capacity, the reversion of Tyr-215 to Thr, Ser, or Asn was sufficient to
increase the virus ability to replicate in a drug-free environment. The same genotypic changes at position 215 rendered the MNR virus
susceptible to AZT and stavudine. Interestingly, the presence of the insertion together with mutation T215Y in an otherwise WT sequence
background was not sufficient to confer high-level resistance to AZT, although its replication capacity was clearly impaired. Therefore, the
RT residue 215 plays a critical role in both replication capacity and drug resistance of multidrug-resistant viruses containing the i69SS.
D 2004 Elsevier Inc. All rights reserved.Keywords: Multidrug-resistant; HIV-1; Reverse transcriptase; 69 insertion; Viral fitnessIntroduction
Human immunodeficiency virus type (HIV-1) infection
is currently treated with highly active three-drug combina-
tion therapies. However, the emergence of drug resistance-
associated mutations is the major limitation to long-term
treatment efficacy. Moreover, the fact that the 20 currently
approved HIV-1 inhibitors for clinical use belong to only
four different drug classes facilitates the appearance of
cross-resistance among different drugs of the same family.
The nucleoside analogue reverse transcriptase inhibitors
(NRTIs) were the first type of compounds used for HIV
treatment and are still part of almost all therapeutical0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.06.006
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NRTI is associated with multiple mutations in the reverse
transcriptase (RT). Certain mutational pathways lead to the
selection of RTs with multi-NRTI resistance (MNR). One
of those patterns involves an insertion of two amino acids
(often Ser–Ser, Ser–Gly, or Ser–Ala) between residues 69
and 70 of HIV-1 RT (Briones and Soriano, 1999; Briones
et al., 2000; De Antoni et al., 1997; de Jong et al., 1999;
Larder et al., 1999; Ross et al., 1999; Sugiura et al., 1999;
Tamalet et al., 1998; Winters et al., 1998). The insertion at
position 69 has been described in about 2% of HIV-1-
infected patients that received prolonged therapy with
zidovudine (AZT) together with (or followed by) admin-
istration of other NRTIs (Van Vaerenbergh et al., 2000).
The insertion is in the h3–h4 hairpin loop at the fingers
subdomain of the RT and appears to be associated with
multiple amino acid substitutions, including AZT-resis-
tance mutations, such as T215Y. By themselves, the
insertions cause low-level resistance to each of the NRTIs
Table 1
Amino acid sequence differences between RTs from WT HIV-1 (BH10
strain) and recombinant virus derived from the multidrug-resistant clinical
HIV-1 isolate (SS)
41 62 67 69 70 108 118 181 184 210 215
WT (BH10) M A D T K V V Y M L T
SSSY – – – S S S – – – – – – Y
SS L V – S S S R I I C I W Y
SS/215S L V – S S S R I I C I W S
SS/215N L V – S S S R I I C I W N
SS/215T L V – S S S R I I C I W –
SS/67N L V N S S S R I I C I W Y
Only those amino acid differences found at codons associated with
resistance to RTs are indicated (D’Aquila et al., 2003). Six different plasmid
constructions were generated containing RT sequences from the wild-type
strain (BH10) and the sequence found in the clinical isolate (SS). The
mutation G333E was also present in SS and mutants derived from this
construct.
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2000; Winters et al., 1998), and drug resistance tests of
recombinant patient isolates containing insertions together
with T215Y/F and other AZT-resistance mutations showed
reduced susceptibility to all NRTI (Dunne et al., 2001;
Hertogs et al., 2000; Larder et al., 1999; Mas et al., 2000;
Masquelier et al., 2001; Petropoulos et al., 2000; Winters
et al., 1998). Insertions between codons 69 and 70 have
also been associated with resistance to tenofovir (Harrigan
et al., 2002; White et al., 2004). The insertion of two
serines at codon 69 (i69SS) appears to be critical to
enhance AZT and stavudine (D4T) resistance in the
sequence context of a multidrug-resistant HIV-1 RT
(Dunne et al., 2001; Hertogs et al., 2000; Larder et al.,
1999; Mas et al., 2000; Masquelier et al., 2001; Petropou-
los et al., 2000; Winters et al., 1998). Phenotypic resis-
tance to those thymidine analogues correlates with an
increased ATP-dependent phosphorolytic activity that facil-
itates the efficient removal of the 3V-terminal nucleotideTable 2
Susceptibility to nucleoside analogue reverse transcriptase inhibitors and replicati
Virus IC50 (AM)a (fold increase)
AZT d4T ddI ddC
WT (BH10) 0.005 0.19 2.03 0.4
T69SSSe 0.002 0.26 1.91 0.1
SSSY 0.02 (4.0) 1.33 (5.5) 2.09 (1.0) 1.5
SS >7.48 (>1600) 2.60 (13.9) 17.64 (8.7) 5.3
SS/67N 3.54 (708) 2.62 (14.0) 9.54 (4.7) 2.6
SS/215T 0.007 (1.4) 0.49 (2.6) 11.61 (5.7) 2.4
SS/215S 0.019 (4.1) 0.32 (1.7) 6.31 (3.1) 1.4
SS/215N 0.006 (1.2) 0.29 (1.6) 4.93 (2.4) 1.2
a The concentration of drug necessary to inhibit viral replication by 50% (IC50) va
relative to the wild-type virus control carrying the RT sequence of BH10 is show
b In absence of drug.
c Exponential growth constant or slope (m) derived from the equation log ( y) = m
t is time in days, and b is the y-intercept.
d 95% confidence intervals (CI).
e IC50 values taken from Mas et al. (2000) for comparative purposes. This virus
serines (T69SSS).from NRTI-terminated primers (Lennerstrand et al., 2001;
Mas et al., 2000, 2002).
In the absence of drugs, the insertion by itself does not
confer any fitness disadvantage when occurring in a WT
sequence context (i.e., HIV-1BH10). However, it contributes
to increase viral fitness of an HIV-1 isolate harboring the
MNR genotype to levels that are roughly similar to those
observed with the WT HIV-1BH10 strain (with or without
the insertion) (Quin˜ones-Mateu et al., 2002). So far, two
amino acid insertions between positions 69 and 70 have
only been reported once in patients with primary HIV-1
infection (Daar et al., 2002). Their low prevalence in HIV-
treated patients suggests that its transmission fitness is also
low.
In this work, we have measured the effect of mutations at
codons 67 (D67N) and 215 (Y215T, Y215S, and Y215N)
on the phenotypic susceptibility to NRTI and replication
capacity of recombinant HIV-1 variants carrying the i69SS
in the sequence background of a clinical multidrug-resistant
isolate (Table 1).Results
Resistance to nucleoside analogue inhibitors
Recombinant HIV-1 clones were assayed to establish
the level of resistance to NRTIs in clinical use (Table 2).
Within the context of a MNR genotype (including the
i69SS), the addition of D67N, an AZT-resistance mutation,
showed a minor effect in NRTI susceptibility. However,
the reversion of Tyr-215 to Thr, Ser, or Asn rendered the
MNR virus susceptible to AZT and D4T (Table 2). These
mutated viruses were also more sensitive to didanosine and
zalcitabine inhibition. All recombinant viruses derived
from the multidrug-resistant strain retained high levels ofon capacity of HIV-1 constructs
Replication capacityb
3TC Slope, m, (pg/ml day)c 95% CId
2 0.63 0.85 0.51–1.2
4 1.84
6 (3.7) 3.36 (5.3) 0.71 0.56–0.87
7 (12.8) >20 (>34) 0.82 0.55–1.1
5 (6.3) >20 (>34) 0.86 0.64–1.1
1 (5.7) >20 (>34) 0.87 0.67–1.1
9 (3.5) >20 (>34) 0.87 0.71–1.0
9 (3.1) >20 (>34) 0.77 0.62–0.93
lues represents the mean of three to six replicates. The fold increase in IC50
n between parenthesis.
t + log (b), where y is a measure of virus quantity (i.e., pg of p24 per ml),
contained an RTBH10 in which codon 69 (Thr) has been replaced by three
Fig. 1. Schematic representation of GeneScan detection for growth
competition experiments. (A) HIV-1 DNA is extracted from the MT4 cells
used in growth competition experiments. Samples are taken at different
times after dual infection with two HIV-1 isolates (i.e., a WT recombinant
clone and an i69SS-containing virus). Two primers, one of them labeled
with FAM, were used to amplify an RT fragment by PCR. (B) Labeled PCR
products were run in a capillary electrophoresis along with DNA size
markers. Two peaks, each of them proportional to the relative among of the
two viral variants in the original sample, appear at the 144 and 150 bp
positions. (C) The sensitivity of the technique was assayed by mixing
different proportions of two plasmids, one WT and another containing the
69 insertion in the RT. The detection is linear down to 10%. See Materials
and methods for experimental details.
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Interestingly, the presence of the insertion together with
mutation T215Y in an otherwise WT sequence background
conferred a moderate increase of AZT resistance.
Replication kinetics
The growth rates of all tested recombinant viruses were
similar to the one shown by WT HIV-1 (Table 2). Moreover,
differences observed between the WT and the virus showing
the lowest replication capacity (i.e., SSSY) were not statis-
tically significant.
Relative replicative fitness in virus mixtures
To measure viral fitness differences more accurately,
dual infections were performed in cell culture. Replication
capacity was determined in vitro relative to the WT at
different multiplicity of infection (MOI) over 28 days. The
proportions of WT and i69SS-containing viruses were
estimated by length polymorphism detection methods
(Fig. 1). Before applying this detection system to growth
competition experiments, we set up the method with
different mixtures of plasmids containing an HIV-1 RT
fragment with and without the i69SS. Fig. 1C demonstrates
an excellent agreement and reproducibility between the
expected and the measured values of dual mixtures of
sequences with and without the i69SS. The method was
sensitive at least down to 10% of one of the viral strains.
Competition growth assays were performed with dif-
ferent MOIs. We could observe differences in the out-
come of the competitions between a MOI of 0.01 and
0.001, the latter one showing the most significant differ-
ences among the different viral strains compared. For
example, at an MOI of 0.01, fitness differences between
the WT virus and the mutant SS/215S were not signif-
icant. However, when the MOI was reduced to 0.001,
the WT tended to outgrow the SS/215S (Fig. 2B). A
similar behavior was observed in fitness competition
assays with WT HIV-1 and mutant SS/67N. While at
an MOI of 0.01, the mutant was slightly overgrown by
the WT virus, at a lower MOI (0.001), the WT viruses
had taken over the population by day 14 of culture (Fig.
2B). Interestingly, antigen p24 levels increased steadily
during the first 6 days postinfection, at least during the
first two passages, when infections were carried out at an
MOI of 0.001 (Fig. 2A). However, at higher MOIs (i.e.,
0.01), maximum p24 levels were already detected within
the first 3 days after infection in all assays. These
results, which were also consistent with simultaneous
determinations of cell viability (data not shown), justify
why the lower MOI is more efficient to distinguish
subtle differences in fitness between the competing
viruses.
All tested viruses had a replication capacity lower than
the WT when assayed in a drug-free environment for anMOI of 0.001 (Fig. 3). Thus, even when infections were
initiated with an excess of mutant virus (right panel of
each competition in Fig. 3), the WT virus outgrew the
mutant viruses SS, SSSY, SS/67N, and SS/215N before
day 15 of culture, while the shift occurred later for
viruses SS/215S and SS/215T. In fact, the loss of fitness
of these two viruses in comparison with the WT strain
did not reach statistical significance. Fitness competition
Fig. 2. Influence of different MOIs in growth competition experiments. (A) Antigen p24 production after HIV-1 infection of MT4 cells at an MOI of 0.01 (top
panel) and 0.001 (bottom panel). Reinfection of fresh cells was performed every 7 days. (B) Changes in the evolution of WT HIV-1 vs. mutants SS/215S or SS/
67N in growth competition experiments set up at different MOIs.
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tions were initiated with an excess of mutant or with an
excess of WT virus. Interestingly, the presence of the
insertion together with mutation T215Y in an otherwise
WT background (as in mutant SSSY) impaired fitness,rendering viruses with a replication capacity similar to
that shown by the SS strain or the SS/67N mutant (Fig.
4). When the SS virus was used for comparison, SS/215T
and SS/215S were significantly fitter (P < 0.05) (Fig. 4).
Recombination between the two input viruses was not
Fig. 3. Replication capacity of different RT mutants containing the 69 insertion vs. a WT HIV-1 strain assayed in growth competition experiments in MT4 cells
and detected by GeneScan. Co-infections were carried out with nonequivalent amounts of mutants vs. a WT HIV-1 strain. Two experiments, each initiated with
a different proportion of the two viruses, are plotted in each panel. (A) SS vs. WT; (B) SSSYvs. WT; (C) SS/215S vs. WT; (D) SS/215T vs. WT; (E) SS/215N
vs. WT; (F) SS/67N vs. WT. Open symbols refer always to the WT HIV-1 strain, and solid symbols refer to the HIV-1 RT mutants containing the 69 insertion.
Proportions of different viral populations containing the 69 insertion in the RT were determined every 3 or 4 days. Error bars represent standard error of three
independent measurements. Data on day 0 refer to input TCID50 proportions.
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the end of the co-culture.Discussion
A dipeptide insertion at position 69 in combination
with T215Y/F and other thymidine-analogue-resistance
mutations has been considered as a mutational pattern
characteristic of MNR. This mutational pattern, however,
is responsible for only a minority of resistant isolates: it
is present in about 1% of the patients treated with at least
one NRTI and 3% of the patients treated with more than
three NRTIs (Stanford HIV RT and Protease Sequence
Database; http://www.hivdb.stanford.edu; Rhee et al.,
2003). Previous reports described the role of the two
serine insertion at positions 69/70 of the HIV-1 RT on
NRTI resistance and the biochemical mechanism in-
volved, as well as their influence on viral fitness in
either a WT RT sequence background or in the context
of a multidrug-resistant RT derived from a clinical isolate(designated as SS) (Mas et al., 2000, 2002; Quin˜ones-
Mateu et al., 2002). In the present study, we analyzed the
effects on viral fitness and NRTI susceptibility of adding
a new mutation in the h3–h4 hairpin loop at the fingers
subdomain of the RT or reverting Tyr-215 to its WT
genotype (Thr-215) or to other less common amino acids
(i.e., Ser or Asn). Our results showed that the introduc-
tion of mutation D67N in the multidrug-resistant SS
variant had no measurable effect on viral fitness or
resistance to NRTIs. However, the reversion of Tyr-215
to Thr, Ser, or Asn in the sequence context of a MNR
background, including the 69 insertion, rendered viruses
susceptible to AZT and D4T, whose viral fitness in-
creased in the absence of drug. Our results indicate that
the RT residue 215 plays a critical role in both drug
resistance and replication capacity of MNR viruses con-
taining the i69SS. In the context of an MNR virus, the
reversion of Tyr-215 to Thr that involves two nucleotide
changes, or its substitution by Ser or Asn, which requires
only one nucleotide substitution, is sufficient to recover
full susceptibility to AZT and D4T due to the loss of the
Fig. 4. Determination of the relative replication efficiencies of recombinant HIV-1 strains containing the 69 insertion in the RT-coding region vs. a WT virus as
determined from growth competition experiments. Horizontal dotted line represents the fitness vector for the WT virus. Other vectors show variations in the
relative amounts of mutant vs. WT ratios during passages in cell culture. Each of the six RT mutants (SS, SSSY, SS/215S, SS/215N, SS/215T, and SS/67N) was
mixed with WT in independent competition cultures at a starting mutant to WT ratio of 4:1. Slopes were calculated by fitting linear models using the method of
least squares. All viruses were less fit than the wild-type (P < 0.01). Asterisks indicate recombinant viruses that are fitter than the SS (P < 0.05). se, standard
error. R2, coefficient of determination.
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2004) as well as to increase the viral replication capacity
in the absence of drugs. However, the interpretation of
the data might be somehow limited by the use of a single
primary isolate-derived RT sequence.
It has been shown that, after discontinuation of AZT
in patients harboring AZT-resistant strains of HIV-1 (i.e.,
isolates carrying mutations M41L, D67N, T215Y/F,
K219Q/E,. . .) or in newly infected individuals who had
acquired an AZT-resistant virus by transmission, resistant
variants were eventually replaced by AZT-susceptible
revertants that often contained unusual amino acids at
codon 215, such as Asp, Asn, Cys, or Ser, through
mutations involving one nucleotide change (de Ronde et
al., 2001; Garcı´a-Lerma et al., 2001; Yerly et al., 1998).
These partial revertants appear to be fitter than the virus
having Tyr-215 when tested in growth competition
experiments (de Ronde et al., 2001; Garcı´a-Lerma et
al., 2001; Yerly et al., 1998). However, those studies
included only viruses with three or less NRTI resistance-
conferring mutations, and none of them contained the
i69SS (de Ronde et al., 2001; Garcı´a-Lerma et al., 2001;
Lukashov et al., 2001; Yerly et al., 1998). In contrast,
our recombinant viruses had a MNR genotype that
included the i69SS and at least 10 RT inhibitor-associated
resistance mutations. It has also been reported that, in
vivo, there is a competitive disadvantage of the insertion
mutant compared to the WT virus when therapy is
withdrawn (Lukashov et al., 2001). However, the pres-
ence of the insertion was always linked to the presence
of Tyr at position 215, making difficult to elucidate
whether the insertion or the change at position 215 wasresponsible for the loss of fitness of the HIV-1 isolates.
In addition, removing the dipeptide insertion from a
MNR HIV-1 isolate did further reduce its viral fitness
(Quin˜ones-Mateu et al., 2002). This would suggest that
the insertion by itself has a limited effect in replication
capacity. In contrast, Asn-215, Ser-215, or Thr-215
appears to increase viral fitness and reduce AZT and
D4T resistance in different sequence backgrounds. To our
knowledge, there is only one report showing co-infection
with an HIV isolate containing the 69 insertion and a
wild-type HIV strain (Daar et al., 2002). This low
transmission rate could be due in part not only to the
low prevalence of the insertion in HIV-treated patients,
but also to a potentially poor transmission of these
variants because of their low viral fitness. Therefore,
the in vivo influence of the reversion from Tyr-215 to
Asn, Ser, or Thr in such MNR context is unknown, but
their clinical relevance cannot be ruled out.
The presence of the 6-bp insertion between codons 69
and 70 allowed us to obtain length polymorphism results
from growth competition experiments involving two HIV-1
strains, one of them containing the insertion. This technique
rendered a high throughput and a dynamic quantification
range easily detecting down to 10% of any of the viral
variants. Sensitivity was two- to three-fold higher than using
relative peak heights in electropherograms obtained by
automated sequencing. To verify that the out-competing
strain was the WT HIV-1 and not a fitter recombinant virus
lacking the 6-bp insertion, we obtained population-based
sequences at the end of all growth dual-competition cul-
tures. All sequences showed that, in agreement with the
length polymorphism results, the dominant virus was the
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individual infectious molecular clones used in replication
kinetics based on levels of the p24 antigen had a stable
genotype over the time of culture.
In this study, we have used recombinant viruses whose
replication kinetics were quite similar. In this setting, the
competitive-culture approach was more efficient than
monitoring viral growth through detection of the p24
antigen in discriminating small differences between viral
strains (Martinez-Picado et al., 1999; Prado et al., 2002;
Quin˜ones-Mateu et al., 2002). Differences in relative
fitness between the two competing recombinant HIV
strains were more clearly observed when dual infections
were performed at lower MOIs. Thus, while marginal or
no viral population changes were observed over time at
an MOI of 0.01, the differences were relevant at a 10-
fold lower infectivity (MOI of 0.001). Although such
effect had never been described for HIV-1, a similar
phenomenon has been observed when two closely related
subpopulations of foot-and-mouth disease virus (FMDV)
were subjected to growth-competition experiments in
BHK-21 cells (Sevilla et al., 1998). One of the popula-
tions was found to have a selective advantage over the
other only when the competition passages were carried
out at low MOI. Conversely, populations coexisted during
serial passages carried out at high MOI, suggesting that
small differences in the interaction of the virus with the
host cell may contribute to a MOI-dependent selective
advantage of one viral subpopulation over a closely
related subpopulation (Sevilla et al., 1998). In our HIV-
1 growth-competition experiments, p24 antigen produc-
tion was saturated after 3 days of culture at higher MOI;
however, it remained closer to an exponential phase over
the 7-day culture at lower MOI (Fig. 2A). This might
indicate that at an MOI of 0.001, there was a higher
number of viral replication cycles allowing the two viral
strains to reach a higher level of competition. Although
speculative, another molecular mechanism underlying
MOI-dependent fitness might rely to functional comple-
mentation between the two viruses at high MOI. Thus,
assuming that infection of susceptible cells by more than
one virus happens more frequently at higher MOI, WT
RT might complement the activity of a slightly less
processive mutant RT.
In conclusion, the RT residue 215 plays a critical role
in both drug resistance and replication capacity of MNR
viruses containing the i69SS. Thus, the reversion of Tyr-
215 to Thr, Ser, or Asn in the sequence context of an
MNR virus is sufficient to recover full susceptibility to
AZT and D4T as well as to increase replicative capacity
in absence of drug. Moreover, Tyr-215 and i69SS were
enough to reduce viral fitness in the absence of high
levels of phenotypic resistance to NRTIs regardless of the
presence of other NRTI-associated mutations. Additional-
ly, we have demonstrated here that fitness differences of
two competing recombinant HIVs are MOI-dependent.Materials and methods
Patient sample
The plasma sample was obtained from a heavily treated
HIV-infected individual as part of a previous study that
screened HIV-1-infected patients for the presence of virus
with insertions in the fingers subdomain of HIV-1 RT
(Briones and Soriano, 1999). The donor was an HIV-
infected 38-year-old man who had been extensively treated
with several RT and protease inhibitors, including an initial
treatment with AZT in monotherapy (1992–1996) and a
current regimen at the time of plasma withdrawal combining
five anti-retroviral drugs (D4T, dideoxyinosine, nevirapine,
saquinavir, and nelfinavir). Viral RNA was extracted from
plasma and the RT-coding region was RT-PCR-amplified
and cloned as previously described (Briones et al., 2000;
Mas et al., 2000). Sequencing of the HIV-1 pol gene showed
that apart from the insertion of two serines between codons
69 and 70, it contained 43 additional mutations scattered
throughout the entire RT-coding sequence, including 10
amino acid substitutions related to drug resistance
(D’Aquila et al., 2003).
Generation of recombinant viruses
The recombinant viruses containing the RT-coding
regions of a WT HIV-1 strain (BH10) or of the MNR
HIV primary isolate mentioned above (SS) were con-
structed as previously described (Mas et al., 2000). Muta-
tions D67N (SS/67N), Y215T (SS/215T), Y215S (SS/
215S), and Y215N (SS/215N) were introduced by site-
directed mutagenesis in a plasmid carrying the nucleotide
sequence encoding the 66-kDa subunit of SS RT (Mata-
moros et al., 2004) (Table 1). In addition, mutation T215Y
was introduced in a plasmid encoding a mutated p66
subunit of BH10 RT, which contained the T69SSS inser-
tion (Mas et al., 2000), to obtain the mutant SSSY
(Matamoros et al., 2004) (Table 1). A PCR-amplified
fragment containing the full-length RT-coding region was
co-transfected with an RT-deleted HXB2-D clone in SupT1
cells (Kellam and Larder, 1994). Harvested viruses were
propagated in MT-4 cells. The 50% tissue culture-infec-
tious dose (TCID50) in each virus stock was determined in
the same cell line by using the method of Reed and
Muench (1938).
Phenotypic analysis
Phenotypic susceptibility to nucleoside RT inhibitors
of the new HIV variants was tested in vitro by the MTT
assay (Pauwels et al., 1988). Phenotypic resistance was
determined by measuring fold increase in 50% inhibitory
concentration (IC50) values compared with the reference
WT HIV-1HXB2 strain carrying the RT-coding region of
BH10.
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Inocula of 5000 TCID50 of each virus were used to infect
5  106 MT-4 cells (multiplicity of infection of 0.001) as
previously described (Martinez-Picado et al., 1999; Prado et
al., 2002). After incubation for 2 h at 37 jC, cells were
washed twice with phosphate-buffered saline and resus-
pended in RPMI 1640 (Sigma) supplemented with 10%
fetal calf serum (Sigma), 10 mM HEPES buffer (Invitro-
gen), 50 mg of penicillin/ml, and 50 mg of streptomycin/ml
(Invitrogen) at a concentration of 0.5  106 cells/ml.
Duplicates of 5-ml cultures were incubated in 6-well tissue
culture plates (Nunc) in the absence of drugs. Supernatants
(200 Al) from each culture were collected every day, and
then an equal volume of culture media was added. Levels of
p24 antigen were quantitated in cell-free culture superna-
tants by using the HIV-1 p24 antigen assay (Innogenetics)
and were used to monitor replication kinetics. Growth
kinetics based on p24 production were analyzed by fitting
a linear model to the log-transformed p24 data from the
replicates for each mutant by maximum likelihood methods
(Martinez-Picado et al., 2000; Prado et al., 2002). For a
given mutant, the growth rate based on p24 production was
assumed to be the same between replicates, but the initial
level of p24 was allowed to vary between replicates accord-
ing to a normal distribution. Missing values were assumed
to be missing at random. This model was found to give a
good fit to the data.
Analysis of relative replicative fitness in virus mixtures
Growth competition assays were performed in MT-4 cells
in absence of drug as described elsewhere (Martinez-Picado
et al., 2000; Prado et al., 2002). Multiplicities of infection
(MOI) of 0.01 and 0.001 were assayed. Infections were
initiated with unequal amounts of two competing virus
variants according to virus infectivity titrations. Unequal
ratios were used based on the rationale that an increase in
proportion of the initially less abundant virus suggests a
relatively better replicative capacity than the competing,
initially more abundant virus, although random factors
cannot be excluded with either unequal or equal starting
ratios. Five-milliliter cultures were maintained in 6-well
tissue culture plates at 0.5  106 cells/ml. At day 3 of the
first passage, half of the culture was replaced with fresh
medium. At day 7, fresh MT-4 cells were reinfected with a
dilution 1:100 of the supernatant and cultured at 0.5  106
cells/ml. Three additional passages were performed in the
same way. Aliquots were removed from the cultures at days
3, 7, 10, 14, 17, 21, 24, and 28, centrifuged, total genomic
DNAwas extracted from the cells (Qiamp DNA blood Mini
kit; Qiagen) for genotypic analysis (Fig. 1), and super-
natants were stored at 80 jC. Levels of p24 antigen were
quantitated in cell-free culture supernatants of all time
points to monitor replication kinetics of the competitions.
The number of viable cells was also determined with trypanblue. Genotyping was performed at the end of each com-
petition by using the d-Rhodamine Terminator Cycle Se-
quencing Ready Reaction Kit (Applied Biosystems) and
subsequent electrophoresis in an automated sequencer (ei-
ther an ABI PRISM 310 or 377; Applied Biosystems). MT-4
cells were also separately infected with mutants in the
absence of WT virus to assess possible spontaneous rever-
sion of the mutated codons.
Length polymorphisms detection
DNA was PCR-amplified in triplicate with primers
RT2696–2725 (5VFAM-AAT TGG GCC TGA AAA TCC
ATA CAA TAC TCC-3V, where FAM is 6-carboxyfluores-
cein) and RT2839–2812 (5V-GGA TGT GGT ATT CCT
AAT TGA ACT TCC C-3V) by using Platinum Taq High
Fidelity polymerase (Invitrogen) and 25 thermal cycles (30 s
at 94 jC, 30 s at 55 jC, and 30 s at 68 jC). One microliter
of PCR products was mixed with 20 Al of formamide and 1
Al of the molecular size marker labeled with carboxytetra-
methyl rhodamine (Applied Biosystems) (Fig. 1A). DNA
fragments were separated under denaturing conditions in a
capillary electrophoresis analysis, and results were analyzed
with the GeneScan software (Applied Biosystems), as
previously described (Martinez-Picado et al., 2002). The
area of each peak divided by the total area of the two peaks
was used to determine the relative proportion of the two
competing variants in each time point (Fig. 1B). Viral RNA
was also extracted from the culture supernatants, reverse
transcribed, and PCR amplified in one step by using the
OneStep reverse transcription-PCR kit (Qiagen) with the
same primers indicated above.
The reproducibility and robustness of the length poly-
morphisms detection method were tested by mixing known
amounts of plasmids that contained the HIV-1 RT-coding
region with and without the i69SS.
Statistical analysis
Statistical analyses were performed using the R language
(http://www.r-project.org) and the SPSS programs ver-
sion10.0.6 (SPSS Inc., Chicago, IL).Acknowledgments
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